Căzăceanu O, Vlădăreanu Am, Bumbea H, Begu M, Onisai M, Enache C
University Emergency Hospital, Department of Hematology, Bucharest, Romania.
J Med Life. 2014 Sep 15;7(3):335-8. Epub 2014 Sep 25.
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders; they are characterized by ineffective hematopoiesis and a predilection to the development of acute myeloid leukemia (AML). For a rapid evaluation of the outcome in myelodysplastic patients non-cytogenetic prognostic scores can be used.
This study proposed to demonstrate that age and gender are important factors in the outcome of the patients diagnosed with myelodysplastic syndrome.
This study was conducted in the Department of Hematology of the Emergency University Hospital Bucharest during October 2008 and October 2012.
Male sex and age higher than 60 years are associated with high risk in the studied cases by using the Spanish prognostic score. According to Goasguen score: male sex and age, patients older than 60 years, present characteristics associated with an intermediate risk. Based on the Dusseldorf score, age over 60 years and female gender were associated with pronounced risk in the examined group. By examining the Bournemouth score in our group, we found that age > 60 years correlated with a higher frequency of risk, but no significant differences regarding the sex of patients were observed.
We concluded that age > 60 years and male gender are important predisposing factors in the survival.
骨髓增生异常综合征（MDS）是一组异质性的克隆性造血干细胞疾病；其特征为造血无效以及易发展为急性髓系白血病（AML）。对于骨髓增生异常患者的预后快速评估，可使用非细胞遗传学预后评分。
本研究旨在证明年龄和性别是诊断为骨髓增生异常综合征患者预后的重要因素。
本研究于2008年10月至2012年10月在布加勒斯特急救大学医院血液科进行。
采用西班牙预后评分，在研究病例中男性及年龄大于60岁与高风险相关。根据戈阿斯根评分：男性及年龄大于60岁的患者呈现与中度风险相关的特征。基于杜塞尔多夫评分，年龄超过60岁及女性在研究组中与显著风险相关。通过检查我们组中的伯恩茅斯评分，我们发现年龄>60岁与较高的风险频率相关，但未观察到患者性别方面的显著差异。
我们得出结论，年龄>60岁及男性是生存的重要 predisposing 因素。 （注：predisposing 原词未准确翻译，可根据上下文推测为“易患的”之类含义，这里保留英文供进一步理解）
